Dec, 2011

U.S.A.
News / Therapeutic Area News
Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL® DosePro® Effective March 31, 2012
SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Read More

Nov, 2011

U.S.A.
News / Therapeutic Area News
Medivation and Astellas Announce Positive Survival Data from Interim Analysis of Phase 3 AFFIRM Trial of MDV3100 in Men with Advanced Prostate Cancer
SAN FRANCISCO, CA and TOKYO -- November 3, 2011 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. announced that the Independent Data Monitoring Committee (IDMC) has informed the...
Read More

Aug, 2011

U.S.A.
News / Therapeutic Area News
Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe
Astellas Pharma Inc. (Tokyo:4503, "Astellas") today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron...
Read More

Jul, 2011

U.S.A.
News / Therapeutic Area News
Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas
WHITEHOUSE STATION, N.J. and DEERFIELD, Ill., July 26, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Astellas US LLC ("Astellas"), the U.S. subsidiary of...
Read More

Jun, 2011

U.S.A.
News / Therapeutic Area News
Astellas Announces New Study Results Showing Increased Survival Rate for Metastatic Pancreatic Cancer
Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data...
Read More